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Summary: N-acetylaspartate (NAA) quantification by I H magnetic resonance spectroscopy has been commonly used to assess in vivo neuronal loss in neurodegencrative disorders. Here, the authors used ex vivo and in vivo IH-magnetic reso nance spectroscopy in rat and primate models of progressive striatal degeneration induced by the mitochondrial toxin 3-ni tropropionate (3NP) to determine whether early NAA deple tions could also be associated with neuronal dysfunction. In rats that were treated for 3 days with 3NP and had motor symptoms, the authors found a significant decrease in NAA concentra tions, specifically restricted to the striatum. No cell loss or dying cells were found at this stage in these animals. After 5 days of 3NP treatment, a further decrease in striatal NAA con centrations was observed in association with the occurrence of Considerable interest in understanding the role and behavior of N-acetylaspartate (NAA) has arisen in recent years because of the fact that this compound contributes to the major resonance seen on I H-magnetic resonance spectroscopy C H-MRS). In addition, because of its al most exclusive localization in neurons in the adult brain, NAA seen in I H-MRS has been used as a marker of neuronal density (Tallan, 1956; Urenjak et aI., 1992) . Accordingly, regional decreases in NAA concentrations have been reported in many experimental and clinical conditions that are associated with actual neuronal cell loss, for example, excitotoxic lesions, ischemia, epilep-dying neurons in the dorsolateral striatum. In 3NP-treated pri mates, a similar striatal-selective and early decrease in NAA concentrations was observed after only a few weeks of neuro toxic treatment, without any sign of ongoing cell death. This early decrease in striatal NAA was partially reversed after 4 weeks of 3NP withdrawal. These results demonstrate that early NAA depletions reflect a reversible state of neuronal dysfunc tion preceding cell degeneration and suggest that in vivo quan tification of NAA I H-magnetic resonance spectroscopy may become a valuable tool for assessing early neuronal dysfunc tion and the effects of potential neuroprotective therapies in neurodegenerative disorders. Key Words: N-acetylaspartate-sia, and neurodegenerative diseases (Ebisu et aI., 1994; Higuchi et aI., 1997; Vermathen et aI., 1997; Lopez Villegas et aI., 1997) . However, more recent data have also shown that NAA depletions could be reversed after therapeutic interventions (Kalra et aI., 1998; Ellis et aI., 1997; Holshouser et aI., 1995; Vion-Dury et aI., 1994) or even spontaneously (De Stefano et aI., 1995) , suggesting that NAA concentration might also represent a reversible spectroscopic marker for neuronal dysfunction. Alterna tively, because intramitochondrial NAA neosynthesis has also been shown to be affected by mitochondrial toxins (Bates et ai., 1996) , NAA depletions could be more simply related to a deficit in the mitochondrial oxidative phosphorylation process.
To study this question further, we used a well characterized model of progressive striatal degeneration in rats and primates that is induced by systemic admin istration of 3-nitropropionic acid (3NP), an irreversible inhibitor of the mitochondrial complex II succinate de hydrogenase. An interesting feature of this model resides in the temporal evolution of the neurodegenerative pro cesses, which progresses from an early stage of neuronal dysfunction without detectable cell death to a more ad vanced stage of actual neurodegeneration characterized by the presence of necrosis and apoptotic features within the caudate-putamen complex (for review, Brouillet et aI., 1999) . In the late stage of the neurotoxic treatment, the 3NP-induced striatal lesion recapitulates most of the histologic features of Huntington disease (HD), that is, bilateral lesions displaying selective loss of striatal pro jection neurons and relative sparing of intrinsic neurons, astrocytes, afferent fibers, and fibers of passage (Beal et aI., 1993; for review, Brouillet et aI., 1999) . Therefore, only the striatal projection neurons, which constitute more than 95% of the total striatal neurons, are signifi cantly affected in this lesion model, whereas striatal as trocytes remain largely spared and able to trigger com pensatory mechanisms (Hassel and Sonnewald, 1995) . In addition, because 3NP readily crosses the blood-brain barrier, the systemic administration of this mitochondrial toxin results in a ubiquitous inhibition of cerebral succi nate dehydrogenase (SDH) (Brouillet et aI., 1998) . Therefore, by comparing two cerebral regions that are differentially vulnerable to 3NP, it is possible to study the effect on regional NAA levels of either a mitochon drial blockade alone (in a region resistant to 3NP, such as the cerebral cortex) or a similar mitochondrial blockade combined with the occurrence of premorbid neurodegen erative events (in a region highly vulnerable to 3NP, such as the striatum).
In the present study, we examined the biochemical, anatomic, and behavioral correlates of NAA depletions in 3NP-treated rats at different stages of the neurotoxic treatment, using an ex vivo I H -MRS approach that yielded highly resolved spectra and provided actual quantification of numerous biologically relevant brain metabolites. To further assess the potential clinical rel evance of these findings, we also observed nonhuman primates to determine whether NAA depletions could also be reversible after 3NP withdrawal. For this pur pose, we took advantage of the 3NP primate model, which is characterized by a striatal degenerative process that is more progressive (15 weeks) than the one ob served in the rat model (6 days) and an in vivo localized I H-MRS approach (Dautry et aI., 1999) to perform a follow-up study of striatal NAA concentrations in a group of 3NP-treated baboons at various stages of the neurotoxic treatment (before any treatment, at an early stage of the neurotoxic treatment [i.e., between 8 and 10 weeks of 3NP treatment], and 4 weeks after termination of the 3NP treatment).
MATERIALS AND METHODS

Chronic 3NP treatment in rats
Male Lewis rats (body weight, 300-350 g; n = 30) were nerability of animals to 3NP toxIcIty increases with age (Brouillet et aI., 1999) , all rats were of the same age (\0 weeks) at the beginning of the neurotoxic infusion. The 3NP (Sigma, Saint-Quentin Fallavier, France) solution was prepared as pre viously described (Brouillet et aI., 1998) . The neurotoxic treat ment consisted of continuous infusion of 3NP for 3 days (n = 9) or 5 days (n = 6) using osmotic minipumps (model 2ML4, Alzet Inc., Palo Alto, CA, U.S.A.) that were implanted subcu taneously under ketamine-xylazine anesthesia in the back of the animals. The 3NP concentration in the minipump was ad justed to the initial weight of each animal so that all rats re ceived the same 3NP regimen corresponding to 38 mg/kg/d. Control animals (n = 9 at 3 days; n = 6 at 5 days) were age-matched Lewis rats implanted with empty mini pumps.
After 3 days or 5 days of the neurotoxin treatment, the rats were killed and their brains were rapidly removed. Because 3NP is active systemically and induces symmetrical bilateral lesions in the striatum, we used the same animal for biochemi cal and histochemical analysis: the brain was cut along the rostrocaudal axis on a cold plate; one brain half was immedi ately frozen in isopentane (-25°C) for SDH histochemistry and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method, and the other brain half was rapidly cut in 2-mm-thick slices from which the striatum and cerebral cortex (mainly corresponding to the somatosensory area) were dissected for extraction of brain metabolites and ex vivo I H-MRS analysis. All experimental procedures were per formed in strict accordance with the recommendation of the European Ethical Community (86/609/EEC) and the French National Committee (87/848) for the Care and Use of Labora tory Animals.
Behavioral evaluation in rats
3NP-treated animals and their corresponding controls were evaluated daily for motor deficits with use of a quantitative neurologic scale. Motor deficits were first determined based on the presence and severity of various motor symptoms, includ ing dystonia (intermittent dystonia of one hindlimb = I; in termittent dystonia of the two hindlimbs = 2; permanent dys tonia of hindlimbs = 3), gait abnormalities (uncoordinated and wobbling gait = 4; lying on one side but showing uncoordi nated movements when stimulated = 5), and near-death re cumbency (almost complete paralysis with rapid breathing = 6). In addition, the ability of the animals to grasp a cage grid with the forepaws for few seconds (able = 0; unable = I) and the ability to remain on a small platform (9 x 5 cm) for more than \0 seconds (able = 0; unable = I) were assessed. A final neurologic score was calculated for each animal as the sum of indices of motor symptoms, grasping, and equilibrium capaci ties (normal animal = 0; maximal neurologic impairment = 8).
Ex vivo I H-MRS and metabolite quantitation in rats
On the brain half that was used for I H-MRS, absolute con centration levels of NAA, aspartate, glutamate, inositol, succi nate, glutamine, alanine, taurine, creatine, and gamma aminobutyric acid (GAB A) were obtained from the striatum and cortex, separately. The striatal and frontal cortex areas were dissected at 4°C from a 2-mm-thick slice, and metabolites were extracted by sonication in 500 fLL of ice-cold O.I-N per chloric acid solution. Protein concentration for each sample was determined in quadruplicate from 5 fLL aliquots using a standard colorimetric technique (Bicinchoninic Acid Protein Assay Reagent, Pierce, Rockford, IL, U.S.A.). Samples were then centrifuged at 15,000 g for 15 minutes at 4°C, and the supernatants were collected and neutralized with 5-N potas sium hydroxide. A second centrifugation, at 15,000 g (\5 min utes, 4°C), was performed, and 400 fLL of the supernatants were lyophilized. Tissue extracts were resuspended in D20 and adjusted to pH 1.3 with DCI in a final volume of 400 IJ.L Each sample was placed in a S-mm nuclear magnetic resonance tube equipped with a coaxial insert containing a reference solution of formic acid (4 1 mM). Measurements were obtained at 2SoC on a Bruker AMX-300WB spectrometer (Ettlingen, Germany) operating at 300 MHz. A fully relaxed one-pulse sequence with water presaturation was used (90° flip angle, 4000 Hz spectral width, 4 K complex points, 10.3 seconds repetition time, 800 signal averages). Proton spectra (Fig. 1) were processed with a I-Hz line-broadening filter and a convolution difference filter (broadening factor = 30 Hz; substraction factor = 0.6) to remove broad baseline signals (Barker et a!., 1993) . The peak area of each metabolite of interest, S m e t' was normalized by the peak area of the formic acid external reference, S ref' The ratio Sme/Sref was converted to the absolute amount of metabolite using a calibration curve previously established with solutions of glycine at various known concentrations. For each sample, the ab solute concentration of metabolites was finally expressed in mmollL . kg protein.
Semiquantitative in situ measurement of SDH inhibition in rats
The second brain half, which was frozen in isopentane (-2S°C), was used, and semiquantitative SDH histochemistry was performed as previously described (Brouillet et a!., 1998) . The frozen brains were sectioned at 20 j-Lm, mounted on glass microscope slides, air-dried for 30 to 60 minutes, and kept at -20°C for I to 2 days before histochemical staining. SDH activity was revealed using succinate as a specific substrate and High-resolution 1 H-nuclear magnetic resonance spectra of perchloric acid extracts in one control (A) and one striatum of a rat treated with 3NP for 5 days (3NP-5d) (8). All chemical shifts are referenced to the standard compound Tri Sillyl Propionate (TSP) methyl peak (not shown) at 0.00 ppm. The metabolites considered in the study include (from left to right) inositol, taurine, aspartate, phosphocreatine and creatine (PCr/Cr), glutamate (Glu), gamma-aminobutyric acid (GABA)/glutamine (Gin), gluta mate/glutamine, acetate, N-acetylaspartate (NAA), GABA, ala nine (Ala), lactate, and succinate. Note the dramatic changes in some metabolites after 5 days of 3NP treatment, in particular the decrease in NAA and the marked increases in succinate and lactate.
nitro blue tetrazolium as an electron acceptor. All sections were first incubated for 10 minutes in O. I-M phosphate-buffered saline (PBS; 0.9% NaCI) at 37°C to activate SDH and then rinsed in a large volume of PBS and incubated for 30 minutes at 37°C in a reaction medium containing 0.3-mM nitro blue tetrazolium, O.OS-M phosphate buffer (pH 7.6), and O.OS-M sodium succinate. Adjacent sections were incubated in the me dium described above but lacked succinate to determine the (nonspecific) staining that was unrelated to SDH activity. Sec tions were then rinsed in cold PBS for S minutes, immersed for a few seconds in deionized water, and air-dried at room tem perature. Images of each section were digitized and regions of interest (i.e., striatum and somatosensory cortex) were analyzed using a video analysis system (IMSTAR, Paris, France) as pre viously described (Brouillet et a!., 1998) . SDH activity was expressed as the optical density unit rate per 30 minutes.
TUNEL method
Evaluation of the number of TUNEL-positive cells was per formed on frozen rat sections adjacent to those used for SDH in situ histochemistry. Sections were postfixed with 4% paraform aldehyde in PBS for 30 minutes, incubated in a solution of 0. 1 % sodium citrate and I % Triton-XIOO for S minutes, rinsed in PBS, incubated in proteinase K (10 j-Lg/mL in PBS, pH 7.4) for S minutes, reimmersed in 4% paraformaldehyde for IS minutes, and rinsed three times in PBS before TUNEL reaction. TUNEL reaction (30 minutes at 37°C) was performed using a commercial kit and according to the manufacturer's instruc tions (Meylan; Roche, France). Incorporation of fluorescein dUTP was analyzed under epifluorescence with an Olympus Provis microscope (Rungis, France). Positive controls con sisted of sections from normal brain treated with DNAse I (O.S j-Lg/mL, lO-mM Tris-HCI, pH 7.S, 10 minutes at room tem perature) or rat brains previously lesioned with 3NP. The TUNEL reactions in 3NP-treated rats were performed twice, in parallels with positive controls (sections from control animals, pretreated with DNAse I).
Chronic 3NP treatment in primates
Four baboons (Papio anubis; body weight, 10-13 kg) re ceived chronic 3NP treatment as previously described (Brouil let et a!., 1995). The 3NP treatment consisted of two daily intramuscular injections of 3NP (given in the legs at 9:00 A.M. and 4:00 P.M.; starting dose: 6 mg/kg per injection), which were progressively increased at weekly intervals (weekly increment: I mg/kg per injection). Serial in vivo 1 H-MRS and MRI inves tigations were performed every fortnight until a significant depletion in striatal NAA concentrations could be detected. On average, -17% of NAA was observed after 8 to 10 weeks of 3NP treatment. At that time point, one baboon was killed (pen tobarbital, 120 mg/kg intravenously) and its brain was pro cessed for histology, whereas the 3NP treatment was stopped in the three remaining animals. Four weeks later, I H-MRS and MRI were performed again on these three animals. Immedi ately after this last nuclear magnetic resonance experiment, the three animals were killed and their brains were processed for histology.
In vivo I H-MRS in primates
In vivo lH-MRS experiments were performed using a Bruker 3T whole-body scanner. Baboons were anesthetized with ket amine-xylazine (IS mg/kg and I.S mg/kg, respectively), and their heads were positioned into a transmit-receive pseudo Helmholtz probe with use of an MRI-compatible head holder, which allows a reproducible positioning of the animal in the scanner. Transverse T I-weighted images were first acquired to localize the spectroscopic volume of interest and to detect the presence of any striatal lesion. Localized water-suppressed proton spectra (Point Resolved Spectroscopy, TRffE = 2500/ 135 milliseconds, 128 scans, 2048 data points, 2500 Hz band width) were then acquired in a 5.2-mL volume of interest en compassing the rostral half of both caudate-putamen nuclei (volume of interest dimensions were 32.5 x 13.3 x 11.5 mm in the x, y, and z directions, respectively; Fig. 2B ). T2 values of NAA were determined by collecting metabolite spectra at dif ferent TEs (60, 90, 135, 180, 225 , and 270 milliseconds) and using a monoexponential curve for fitting. Water transverse relaxation in the spectroscopic volume of interest was investi gated by fully relaxed single-scan spectra at different TEs (30, 45, 68, 10 I, 200 , 500, 800, and 1500 milliseconds) and ana lyzed using a biexponential fit. The calculated brain water sig nal intensity at TE = 0 was used as an internal reference for calculation of the metabolite concentrations and corrected for cerebrospinal fl uid contamination (Ernst et aI., 1993) . Nuclear magnetic-resonance-visible water was assumed to represent 71.3% (average of water content in gray and white matter) of brain tissue volume, and brain tissue density was taken as 1.05 mg/mL (Kreis et aI., 1993) . Data processing was performed as previously described (Dautry et aI., 1999) . Absolute NAA con centrations in the striatum of primates were obtained and ex pressed as mmollL . kg wet tissue.
Histology in nonhuman primates
Within 3 to 12 hours after the last 'H-MRS scan, baboons were anesthetized (ketamine-xylazine mixture, 15/1.5 mg/kg intramuscular), and then received an overdose of pentobarbital (120 mg/kg intravenously). Finally, animals were perfused transcardially with ice-cold 1% paraformaldehyde in phosphate buffer preceding 4% paraformaldehyde for 8 to 9 minutes. The brain was immediately removed from the skull, cut into 2-cm thick coronal blocks, postfixed for 6 to 8 hours in 4% para formaldehyde at 4°C, and cryoprotected in a series of graded sucrose solutions (12%, 16%, and 18%) in PBS. The blocks were frozen on dry ice and sections (40 f.lm) were cut on a freezing microtome (Microm; Francheville, France). The sec tions from each block were kept in anatomic series, and every 10th section was stained with gallocyanin. The remaining sec tions were cryoprotected with a solution of 30% glycerol and 30% ethylene glycol in 0.05-M PBS and stored at -20°C. To differentiate between alterations in neuronal densities and changes caused by neuronal dysfunction, two different antibod ies were used: a mouse monoclonal antibody (NeuN, diluted 1:1000, Chemicon International Inc., Temecula, CA, U.S.A.), which is specific of vertebrate neuron-specific nuclear protein expressed by most neurons, and an antirat calbindin-D28k rab bit serum (diluted 1:3000, Swant, Bellinzona, Switzerland), which labels a calcium binding protein expressed by a subpop- ulation of striatal projection neurons. In addition, other cal cium-binding proteins or markers expressed by striatal inter neurons were studied using sera raised against calretinin (di luted 1:5000, Swant), parvalbumin (diluted 1:3000, Swant), or choline acetyltranferase (diluted I: 10,000, Chemicon Interna tional Inc.). All antibodies were used according to the follow ing protocol: after 48 hours of incubation in the first antibody at room temperature, sections were processed according to the avidin-biotin method (Hsu et aI., 1981) with tyramine ampli fication (Berghorn et aI., 1994) , except for the NeuN antibody.
TUNEL labeling was also performed in selected baboon brain sections taken at the level of the caudate-putamen com plex. For this purpose, brain sections were mounted on gelatin coated slides, air-dried, rehydrated and incubated in a solution of 0.1% sodium citrate and 1% Triton-XIOO for 30 minutes, rinsed in PBS, incubated in proteinase K (I mg/mL in PBS, pH 7.4, 5 minutes), then incubated in 4% paraformaldehyde for 15 minutes, and finally rinsed three times in PBS before TUNEL reaction. TUNEL reaction and positive controls (DNAse I)
were processed as for the rat sections (30 minutes at 37°C).
Statistical analysis
Results were expressed as means ± standard deviations. Sta tistical analysis included paired or unpaired Student t tests and one-way analysis of variance preceding a Protected Least Sig nificant Difference Fisher test.
RESULTS
SDH activity, TUNEL-positive cells, and motor deficits in 3NP-treated rats
In rats, a general decrease in SDH activity was ob served in the whole brain section of the animals treated with 3NP for 3 days, as compared with the control group (Figs, 3B and 3C) . Semiquantitative measurements con firmed that 3NP treatment induced a highly significant SDH inhibition (Fig. 4A , P < .00 1 vs. controls) both in the striatum (-57.2% ± 5.3%) and cerebral cortex (-52.7% ± 9.0%). At this stage of neurotoxic treatment, there was no difference in the degree of SDH inhibition between the two structures. The ratio of SDH activity between the striatum and cortex determined in the rats treated with 3NP for 3 days (1.06 ± 0.08) was similar in controls (1.04 ± 0.02), suggesting that no ongoing de generation was taking place in the striatum of the rats treated with 3NP for 3 days. In both structures, SDH inhibition was associated with an increase in succinate C. days (G) with 3NP. Note that TUNEL-positive cells were only observed in the dorsolateral striatum of the rats treated for 5 days with 3NP. The insert in (E) shows a TUNEL-Iabeled section from a control rat brain pretreated with DNAse I to induce DNA fragmentation and processed in parallel as a positive control. Calibration bar: 1 mm (8 to 0) and 20 J.Jm (E to G).
concentrations (striatum, 19.9 ± 2.2 mmollL . kg; cortex, 15.2 ± 2.2 mmol/L . kg protein) as determined by ex vivo l H-MRS (Fig. 4B) . Remarkably, the succinate concen tration in the striatum was significantly higher than in the cortex (P < 0.00 1, Student paired t test), suggesting that for a similar level of irreversible inhibition of SOH, 3NP produced a stronger inhibition of the oxidative metabo lism in the striatum, compared with the cerebral cortex. In the 5-day 3NP-treated group, a further decrease in SOH activity was observed in the striatum (-70.5% ± 7.7%) but not in the cerebral cortex (Figs. 3D and 4A ). The striatum/cortex ratio of SOH activity in rats treated with 3NP for 5 days (0.57 ± 0.05) was significantly decreased (P < 0.000 1) as compared with controls (1.01 ± 0.03), suggesting the occurrence of an actual neuronal loss in the striatum of the rats treated with 3NP for 5 days. At this time point, SDH inhibition in both struc tures was also associated with succinate accumulation, which was further increased in the striatum but not in the frontal cortex (Fig. 4B ), as compared with 3-day 3NP treated extracts (analysis of variance, P < .0002, PLSD Fisher). The presence of dying cells with DNA fragmen tation was tested in parallel at the two different time points (i.e., after 3 days and 5 days of 3NP treatment using the TUNEL method). No TUNEL-positive nuclei were observed in the striatum of control animals or ani mals treated with 3NP for 3 days (Figs. 3E and 3F), contrasting with the numerous TUNEL-positive nuclei observed in the lateral striatum of the rats treated with 3NP for 5 days (Fig. 30) . The presence of an ongoing process of degeneration in rats treated with 3NP for 5 days accounted, at least partially, for the stronger de crease in SDH activity observed at this stage in the stria tum as compared with the cerebral cortex (Fig. 3D ).
Behavioral observations in the same groups showed the presence of abnormal movements after only 3 days of in the striatum (open bars) and in the frontal cortex (solid bars) of rats treated for 3 days (3NP-3d, n = 9) or for 5 days (3NP-5d, n = 6) with 3NP. Significant differences in the degree of SDH inhibition between these two structures were only observed in the 3NP-5d extracts (* P < 0.001, paired
Student's t-test). Data are expressed as means ± SD. Succinate concentra tion was statistically higher in the stria tum than in the cerebral cortex after 3 days of 3NP (P < 0.001, paired Stu dent's t-test). After 5 days of 3NP treatment, a further increase in succi nate concentration was detected in the striatum, whereas no additional change could be observed in the cortex. Data are expressed as means ± SD.
3NP treatment (gait abnormalities, bradykinesia, and tran sient leg dystonia), resulting in a progressive decrease in locomotor activity (neurologic score: 2.77 ± 0.22). After 5 days of 3NP treatment, a significant worsening of the motor syndrome was observed (neurologic score: 3.50 ± 0.22, P < 0.04), compared with 3 days of 3NP treatment.
Ex vivo I H-MRS studies in striatum of 3NP-treated rats: 3 days versus 5 days
In the group treated with 3NP for 3 days, there was a significant decrease in concentrations of NAA (-15%), aspartate (-55%), glutamate (-48%), and glutamine (-40%) in the striatal extracts, whereas the concentration of alanine was strongly increased (+53%, Table I ). In the striatal extracts of the 5-day group, NAA and aspartate concentrations were further decreased, whereas deple tions in glutamate and increases in alanine remained stable, as compared with the 3-day 3NP-treated extracts. A partial but significant recovery in glutamine concen tration was observed in the extracts between 3 and 5 days of 3NP treatment. In addition, the concentrations of ino sitol and taurine in the 5-day 3NP-treated extracts were significantly increased (+2 1 and +37%, respectively), compared with control values. Finally, GABA and cre atine levels remained unaffected by either 3 or 5 days of 3NP treatment, suggesting that striatal cell loss was not severe in 5-day group.
Ex vivo I H-MRS studies in 3NP-treated rats:
striatum versus cortex
In the 3NP-treated rats, one striking difference be tween the striatum and cortex was that cortical levels in NAA, inositol, and glutamine remained totally unaf fected by 3NP, both in the 3-day and the 5-day extracts, as compared with controls (Table 1 , bottom panel), whereas all striatal concentrations in these metabolites were strongly affected by 3NP at both time points for NAA and glutamine. Furthermore, despite a similar de gree of SDH inhibition observed in both structures after 3 days of 3NP treatment, the decreases in aspartate and glutamate were less important in the cortex than in the striatum. In addition, whereas a significant recovery in the concentrations of these two metabolites was observed in the cortical extracts, striatal aspartate and glutamate levels remained severely affected in the 5-day extracts. Similarly, whereas a moderate increase in alanine and taurine concentrations was observed in the cerebral cor tex of the animals treated with 3NP for 5 days, a marked increase in the absolute concentrations of these two me tabolites was found in the striatum at the same time point.
In vivo I H-MRS studies in baboons
As shown in Figure 5A , a significant decrease in ab solute striatal NAA concentrations (-17%, P < .03, analysis of variance PLSD Fisher, n = 4,) was observed in baboons after 8 to 10 weeks of 3NP treatment, com pared with the control values determined in the same animals (spectra representation are shown in Figs D28k, a marker expressed by a subpopulation of efferent striatal neurons. All sections were processed in parallel under the same experimental conditions. As compared with controls (E), note the marked depletion in calbindin-028k immunoreactivity after 10 weeks of 3NP treatment (F) and the partial recovery after 4 weeks of 3NP withdrawal (G). In contrast, there was no marked change in the density of NeuN immunopositive neurons between control animals (8) and 3NP-treated animals (C and D), indicating that 10 weeks of 3NP treatment was unable to induce any detectable cell loss in the striatum in the primates (calibration bar: 250 �m).
in any animal. After 4 weeks of 3NP withdrawal, the decrease in striatal NAA was no longer significant (Fig.  SA, 3NP withdrawal) . Again, this time point was not associated with any detectable striatal lesion on the T 1-weighted MRI examination.
Immunohistology in the striatum of baboons
In the baboon that was killed after presenting a sig nificant decrease in striatal NAA concentration, no major structural changes were observed post mortem in the dorsolateral putamen on sections immunolabeled for NeuN, a neuronal marker (Figs. SB-D) , or processed by the TUNEL method (data not shown). However, when calbindin-D28K (a selective marker of the striatal pro jection neurons) was used (Figs. 5E-0) , a major de crease in immunoreactivity could be noted in the dorso lateral putamen and caudate nucleus (Fig. SF) , compared with control data (Fig. SE) . In marked contrast to these alterations, which were specific to the medium-sized spiny neurons, no changes were observed in other striatal cell types, such as the calretinin-immunopositive, parv albumin-immunopositive, and choline-acetyltransferase immunopositive interneurons (data not shown). In the three baboons studied after 4 weeks without 3NP treat ment, a partial recovery in calbindin-D28K immunore activity was observed in both the dorsolateral putamen and the caudate nucleus (Fig. SO) .
DISCUSSION
Recent studies on cell death and regenerative mecha nisms in experimental models of neurodegenerative disorders have suggested that the functional status of neurons could follow a continuum of different states, ranging from health to metabolic distress, neuronal dys function, and finally ongoing cell death. These different states are likely associated with varying degrees of en ergy metabolism impairment, free radicals production, electrophysiologic dysfunction, loss of calcium homeo stasis, and, possibly, selective activation of cell death biochemical pathways, which eventually lead to actual neurodegeneration characterized by irreversible struc tural damages, such as plasma membrane disruption and nuclear DNA fragmentation (lsacson, 1993) . From this neuronal health concept, the idea of neuroprotection has emerged, and numerous investigators are now focusing on discovering reagents that are able to rescue neurons from death. However, the success of such a neuroprotec tive strategy will be highly dependent on our ability to identify the correct time window for therapeutic inter vention, which itself is linked to the identification of specific in vivo markers for the premorbid state of neu ronal dysfunction (Bazzett et aI., 1995) . The present study identifies NAA as one such neuron-specific in vivo marker that can be depleted in a cerebral region, reaching a state of premorbid neuronal dysfunction . Early NAA depletions and metabolic distress It has been recently proposed that NAA depletions may be caused by the direct inhibition of the mitochon drial oxidative phosphorylation (Bates et aI., 1996) . Ac cording to this hypothesis, the mitochondrial blockade by various toxins produces a loss of ATP, which directly affects the energy-dependent glutamate-aspartate trans locase that is responsible for the transport of glutamate into the mitochondrial matrix. Because glutamate is the major source of aspartate converted into NAA by the transaminase L-aspartate N-acetyl transferase, it is pro posed that inhibition of the mitochondrial oxidative phosphorylation process affects NAA production. How ever, the present rat and primate studies suggest a more complex explanation. We found that, in 3NP-treated rats, significant striatal NAA depletion could be observed in absence of dying cells, evidenced by the lack of striatal TUNEL-positive cells, the preservation of the striatum! cortex ratio of SDH activity, and the preservation of OABA concentration. In 3NP-treated primates, a signifi cant NAA depletion was also found at the early stage of intoxication in the absence of obvious striatal lesions, as assessed by MRI and histologic evaluation. It is unlikely that the NAA depletion produced by 3NP treatment is directly related to the partial blockade of SDH because no NAA depletion was found in the cerebral cortex of 3NP-treated rats, although this cerebral region displayed a level of SDH inhibition similar to that found in stria tum. Therefore, the partial blockade of the respiratory chain is not by itself sufficient to induce NAA depletion. Moreover, the significant decrease in aspartate (the direct precursor in the NAA synthesis) observed in the cortical extracts was not associated with significant NAA deple tion. Therefore, the selective depletion of NAA in the striatum might be more related to an inherent vulnerabil ity of striatal neurons to mitochondrial challenges. The higher accumulation of succinate and greater depletions in aspartate and glutamate levels observed for a similar degree of SDH inhibition in the striatum, compared with the cortex, suggest that, in the striatum, the oxidative metabolism (tricarboxylic acid cycle and respiratory chain) is more prone to be functionally affected, com pared with the cerebral cortex. Although the exact mechanism underlying this phenomenon is still un known, it is consistent with the preferential vulnerability of the striatum to 3NP-induced neurodegeneration (Beal et aI.,1993; Brouillet et aI., 1995; Brouillet et aI., 1998; for review, Brouillet et aI., 1999) .
Early striatal NAA depletions are associated with a premorbid state of neuronal dysfunction
In rats, apart from the region-selective NAA deple tions, another main difference between striatal and cor tical extracts after 3 days of 3NP treatment was the marked and sustained increases in alanine observed in the striatum. Alanine is a glia-derived metabolite known to be involved in the metabolic trafficking between neu rons and astrocytes and known to serve as a means of replenishing neuronal amino acid pools (Forissier and Baverel, 198 1; Shank et aI., 1985; Westergaard et aI., 1993; Tsacopoulos et aI., 1994; Gamberino et aI., 1997) . Accordingly, one may speculate that the marked increase of alanine in the striatum reflects a glial activation taking place in this structure, possibly in response to the severe impairment in energy metabolism occurring in the striatal neurons. There was no such phenomenon ob served in the cortical extracts, further indicating that, even if cortical neurons do suffer from the metabolic distress induced by 3NP, this impairment is not sufficient in itself to increase the metabolic coupling between glial cells and neurons. Consistent with the behavioral obser vations obtained in these animals and indicating the pres ence of abnormal movements, all of the present data demonstrate that the early loss in striatal NAA correlates with severe neuronal dysfunction, not only with meta bolic impairment. In addition, the lack of DNA strand breaks (TUNEL-positive cells) in the striatum of rats treated with 3NP for 3 days, as well as the ubiquitous decrease in SDH activity and the normal GABA concen tration in the structure, argues against the idea that cell loss could have significantly contributed to the NAA depletion observed at this early stage of treatment. It is, therefore, reasonable to consider that NAA depletions at this stage are mainly, if not exclusively, associated with neuronal dysfunction, preceding the selective degenera tion of the striatal projection neurons and characterized by neuronal distress, impaired neurotransmission, and metabolic compensation by local astrocytes. This idea is further reinforced by the data obtained in the rats treated with 3NP for 5 days. This late stage of 3NP treatment is characterized by a further decrease in striatal NAA con centrations and a worsening of the behavioral deficit, and it is associated with the presence of TUNEL-positive neurons in the dorsolateral striatum. These changes are also correlated with significant increases in inositol and taurine and a further loss of SDH activity in the striatal extracts. Whereas the presence of TUNEL-positive nu clei could be interpreted in terms of DNA damage pre ceding cell death, alterations in inositol and taurine are interpreted as indirect indices of severe neuronal insult. Moreover, these two metabolites are thought to be os moregulatory and antiexcitotoxic molecules (Thurston et aI., 1989; Huxtable, 1992; Oja and Saransaari, 1996; French et aI., 1986) , and an increase in their concentra tions correlates with various pathologic conditions, in cluding edema and excessive activation of the N-methy1-o-aspartate receptors (Menendez et aI., 1993; Shibanoki et aI., 1993) . These conditions are largely involved in the cell death mechanisms induced by 3NP (Brouillet et aI., 1999) . It is, therefore, possible that part of the large NAA depletion observed in rats treated with 3NP for 5 days, compared with rats treated for 3 days, is caused by on going striatal degeneration added to the NAA depletion that results from neuronal dysfunction. However, it should be pointed out that, even if the presence of TUNEL-positive nuclei and profound decrease in SDH activity could be illustrated in the dorsolateral striatum of the rats treated with 3NP for 5 days, these features of structural cell damage were not associated with major GABAergic cell loss, as evidenced by normal GABA concentrations. This suggests that, even in the rats treated with 3NP for 5 days, the contribution of neuronal loss to the observed NAA depletion must be minimal. This further validates the assertion that the early NAA depletion observed after 3 days of 3NP reflects a premor bid state of a possibly reversible neuronal dysfunction.
Early striatal NAA depletions are partially reversible in chronically 3NP-treated primates
To further assess the hypothesis that NAA depletion could serve as an index of premorbid neuronal dysfunc tion, the potential reversibility of early NAA depletions was tested in baboons that were chronically treated with 3NP, using in vivo I H-MRS. Indeed, whereas the serial assessment of striatal NAA showed that, in agreement with a previous study (Dautry et aI., 1999) , NAA con centrations were significantly diminished after 8 to 10 weeks of 3NP treatment in the four baboons, as com pared with control values (i.e., before 3NP treatment), this decrease was no longer significant after 4 weeks of 3NP withdrawal. This finding is consistent with results obtained from the rats previously reported in the present study, and it suggests that, in the early phase of the 3NP treatment, striatal NAA depletions in the primate model are not caused by cell loss but mainly by neuronal dys function. Consistent with this hypothesis, no striatal le sion could be detected in any baboon, either in vivo using TI-or T2-weighted MRI or post mortem using NeuN immunocytochemistry or TUNEL labeling. However, in the one animal examined immediately after the last 3NP injection (i.e., after 10 weeks of continuous 3NP treat ment), the depletion of -17% in NAA was associated with a major decrease in calbindin immunoreactivity but with no change in NeuN immunolabeling. This major decrease in calbindin immunoreactivity, reflecting neu ronal dysfunction, is consistent with an impairment in the intracellular calcium buffering capacity of a subpopula tion of striatal GABAergic projection neurons, inciden tally known to be particularly vulnerable to both 3NP treatment and the neurodegenerative process of HD (Seto-Ohshima et aI., 1988; Brouillet et aI., 1999) . Inter estingly, as was the case in the rat model, the early NAA depletions observed in the primate model were associ ated with a state of premorbid neuronal dysfunction pre viously defined for striatal neurons as being associated with a "widespread transient decrease in calbindin, not associated with neuronal cell loss" (Bazzett et al., 1995) .
CONCLUSION
The present findings may have important clinical im plications in the search for a treatment of neurodegen erative diseases, in particular HD and Parkinson disease. Finding markers for the chain of events preceding actual neuronal degeneration is required to define the onset of neuronal dysfunction and the optimal time window for therapeutic intervention. In the future, in vivo serial I H-MRS assessment of NAA concentrations might be come a prominent tool, making it possible to characterize these early stages of neurodegenerative disorders that are mainly associated with neuronal dysfunction and to as sess the potential efficacy of neuroprotectiveineuro trophic interventions. Recent studies on animal models of HD have already suggested that trophic factors, such as ciliary neurotrophic factor, could be efficient in slow ing down the degenerative processes of HD (Emerich et aI., 1997) . In this context, the present study strongly suggests that serial assessment of NAA concentrations using I H-MRS is essential to this aim.
